Compare NMM & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NMM | NEO |
|---|---|---|
| Founded | 2007 | 2001 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2007 | 2008 |
| Metric | NMM | NEO |
|---|---|---|
| Price | $91.53 | $19.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $85.00 | $13.38 |
| AVG Volume (30 Days) | 129.3K | ★ 1.9M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.57 | $10.63 |
| Revenue Next Year | $3.66 | $9.73 |
| P/E Ratio | $7.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.02 | $7.07 |
| 52 Week High | $95.00 | $20.05 |
| Indicator | NMM | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 57.52 | 61.61 |
| Support Level | $69.21 | $16.87 |
| Resistance Level | $91.96 | $19.76 |
| Average True Range (ATR) | 2.11 | 0.83 |
| MACD | -0.67 | -0.00 |
| Stochastic Oscillator | 53.94 | 78.03 |
Navios Maritime Partners LP is an international owner and operator of dry cargo and tanker vessels. Its vessels are generally chartered-out under short-term, medium-term and long-term time charters with an average remaining charter duration of approximately 2.1 years to a group of counterparties. Its fleet consisted of dry bulk vessels, containerships and tanker vessels, including two newbuilding capesize vessels, newbuilding containerships and newbuilding tankers. It operates in single segment.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.